The Chan Zuckerberg Initiative's Biohub is opening a new funding round aimed at the rare disease community while simultaneously expanding its artificial intelligence drug repurposing partnership with Every Cure. The move signals a broadening commitment by one of philanthropy's best-resourced science programs to a corner of medicine where commercial incentives alone have long fallen short.
What Drug Repurposing Is and Why It Changes the Math
Drug repurposing means finding new therapeutic uses for medicines that are already approved — essentially asking whether a drug developed for one disease might work against another. For rare diseases, this approach carries particular weight. Because patient populations are small, the traditional path of discovering and approving a brand-new compound is rarely profitable enough to attract private capital. Repurposing shortcuts that economics: the drug's safety profile is already established, which compresses both the timeline and the cost of getting from hypothesis to human use.
Every Cure is built around accelerating exactly this process using artificial intelligence. By training models on existing biomedical data, the organization tries to surface matches between approved drugs and diseases that human researchers might not have spotted — or might not have had the resources to pursue.
What the Biohub Is Adding
The Biohub's new grants will extend support directly to the rare disease community, broadening the circle of researchers and organizations that can tap into the initiative's resources. At the same time, the expansion of the Every Cure partnership suggests the Biohub is doubling down on AI as the mechanism for finding drug-disease connections at scale, rather than funding individual discovery projects one at a time.
Who Gains and What Comes Next
Rare disease patients and the advocates who fund research on their behalf stand to benefit most directly. Philanthropic capital filling gaps that venture investment and large pharmaceutical budgets leave open has become a familiar pattern in this space, and the Biohub has the scale to move the needle. Whether the AI-assisted repurposing work translates into approved therapies — and how quickly — will be the measure that matters when the next funding cycle opens.